Cargando…

Optimization of Luminescent Assay for Screening of Cyclin-Dependent Kinase 2 Inhibitors

Cyclin-dependent kinases are most extensively studied targets for cancer chemotherapy since the tumor cells exhibit false checkpoints and can proliferate even if the genome is compromised. Cyclin-dependent kinases ensure the tight regulation of the cell cycle execution by mediating phosphorylation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Suthar, M. P., Patel, M. M.
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003159/
https://www.ncbi.nlm.nih.gov/pubmed/21188035
http://dx.doi.org/10.4103/0250-474X.70472
_version_ 1782193828366647296
author Suthar, M. P.
Patel, M. M.
author_facet Suthar, M. P.
Patel, M. M.
author_sort Suthar, M. P.
collection PubMed
description Cyclin-dependent kinases are most extensively studied targets for cancer chemotherapy since the tumor cells exhibit false checkpoints and can proliferate even if the genome is compromised. Cyclin-dependent kinases ensure the tight regulation of the cell cycle execution by mediating phosphorylation of cellular proteins. Deregulation of the cyclin-dependent kinase 2 activity by cellular and external factors leads to many diseases like cancers. Different methods like radiolabeled, fluorescence and luminescence are available for screening of library of compounds against kinases. However, bioluminescent methods offer several advantages like low background and no effect of fluorescent compound interference. Present study is focused on development, optimization and validation of cyclin-dependent kinase 2 assay which is suitable for identification potent and selective, ATP competitive and non-competitive inhibitors of cyclin-dependent kinase 2. The aim of present investigation was to optimize the assay for cyclin-dependent kinase 2/cylin A and cyclin-dependent kinase 2/cyclin E with use of bioluminescence based biochemical reaction. Both cyclin-dependent kinase 2 which are cyclin-dependent kinase 2/cyclin A and cyclin-dependent kinase 2/cyclin E complexes, have different affinity for ATP. Therefore, both isoform analogs of cyclin-dependent kinase 2 were optimized separately. Optimum cyclin-dependent kinase 2/cyclin A and cyclin-dependent kinase 2/cyclin E concentration were found to be 250 ng/well and 200 ng/well, respectively. Optimum substrate (histone H1) concentration was found to be 2.5 mg/ml for both cyclin-dependent kinase 2 analogs. Optimum reaction time was found to be 20 min for both cyclin-dependent kinase 2/cyclin complexes.
format Text
id pubmed-3003159
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-30031592010-12-23 Optimization of Luminescent Assay for Screening of Cyclin-Dependent Kinase 2 Inhibitors Suthar, M. P. Patel, M. M. Indian J Pharm Sci Research Paper Cyclin-dependent kinases are most extensively studied targets for cancer chemotherapy since the tumor cells exhibit false checkpoints and can proliferate even if the genome is compromised. Cyclin-dependent kinases ensure the tight regulation of the cell cycle execution by mediating phosphorylation of cellular proteins. Deregulation of the cyclin-dependent kinase 2 activity by cellular and external factors leads to many diseases like cancers. Different methods like radiolabeled, fluorescence and luminescence are available for screening of library of compounds against kinases. However, bioluminescent methods offer several advantages like low background and no effect of fluorescent compound interference. Present study is focused on development, optimization and validation of cyclin-dependent kinase 2 assay which is suitable for identification potent and selective, ATP competitive and non-competitive inhibitors of cyclin-dependent kinase 2. The aim of present investigation was to optimize the assay for cyclin-dependent kinase 2/cylin A and cyclin-dependent kinase 2/cyclin E with use of bioluminescence based biochemical reaction. Both cyclin-dependent kinase 2 which are cyclin-dependent kinase 2/cyclin A and cyclin-dependent kinase 2/cyclin E complexes, have different affinity for ATP. Therefore, both isoform analogs of cyclin-dependent kinase 2 were optimized separately. Optimum cyclin-dependent kinase 2/cyclin A and cyclin-dependent kinase 2/cyclin E concentration were found to be 250 ng/well and 200 ng/well, respectively. Optimum substrate (histone H1) concentration was found to be 2.5 mg/ml for both cyclin-dependent kinase 2 analogs. Optimum reaction time was found to be 20 min for both cyclin-dependent kinase 2/cyclin complexes. Medknow Publications 2010 /pmc/articles/PMC3003159/ /pubmed/21188035 http://dx.doi.org/10.4103/0250-474X.70472 Text en © Indian Journal of Pharmaceutical Sciences http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Suthar, M. P.
Patel, M. M.
Optimization of Luminescent Assay for Screening of Cyclin-Dependent Kinase 2 Inhibitors
title Optimization of Luminescent Assay for Screening of Cyclin-Dependent Kinase 2 Inhibitors
title_full Optimization of Luminescent Assay for Screening of Cyclin-Dependent Kinase 2 Inhibitors
title_fullStr Optimization of Luminescent Assay for Screening of Cyclin-Dependent Kinase 2 Inhibitors
title_full_unstemmed Optimization of Luminescent Assay for Screening of Cyclin-Dependent Kinase 2 Inhibitors
title_short Optimization of Luminescent Assay for Screening of Cyclin-Dependent Kinase 2 Inhibitors
title_sort optimization of luminescent assay for screening of cyclin-dependent kinase 2 inhibitors
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003159/
https://www.ncbi.nlm.nih.gov/pubmed/21188035
http://dx.doi.org/10.4103/0250-474X.70472
work_keys_str_mv AT sutharmp optimizationofluminescentassayforscreeningofcyclindependentkinase2inhibitors
AT patelmm optimizationofluminescentassayforscreeningofcyclindependentkinase2inhibitors